Clinical Trial Update: Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PET [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating imaging biomarkers with 18F-DTBZ and Florbetapir F-18 PET to study non-motor symptoms in Parkinson's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• 18F-DTBZ (fluorine-18 labeled dihydrotetrabenazine)
• Florbetapir F-18 (florbetapir F-18)

Snippet

Sponsor: Chang Gung Memorial Hospital | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED